Enterprise record

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:cca4cc15-364f-4c52-9c39-34f3cf20478aVersion: public-1As of: unavailable

22 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 4 claims
    • Legal Name: Xenon Pharmaceuticals Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 29, 2026

  2. SEC DEF 14A 0001193125-26-170320

    sec def 14a · Source published: Apr 22, 2026 · Retrieved: Sep 14, 2026

    Supports 9 claims
    • Leadership Role: Dawn A. Svoronos: Chair of the Board and Lead Independent Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Elizabeth Garofalo: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Gary Patou: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Ian C. Mortimer: President, Chief Executive Officer and Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Andrea DiFabio: Chief Legal Officer and Corporate Secretary · Claim reviewed: Sep 29, 2026
    • Leadership Role: Christopher Kenney: Chief Medical Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Darren Cline: Chief Commercial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Ian C. Mortimer: President and Chief Executive Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Thomas Kelly: Chief Financial Officer · Claim reviewed: Sep 29, 2026

  3. DEF 14A xene-20260422.htm

    sec proxy · Source published: Apr 22, 2026 · Retrieved: Sep 2, 2026

    Supports 9 claims
    • Leadership Role: Ann Arbor: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Baie D’Urfe: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Darren Cline: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Gillian Cannon: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Justin Gover: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Los Altos Hills: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: North Vancouver: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Patrick Machado: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Steven Gannon: Director · Claim reviewed: Sep 29, 2026